TRIB3 and atherosclerosis: These findings underscore the critical role of the ATF4-TRIB3 signaling axis in impairing efferocytosis in atherosclerosis and other dyslipidemic conditions, suggesting that therapeutics targeting this pathway could promote efferocytosis and accelerate the resolution of inflammation.